Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Decreases By 17.8%

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 7,190,000 shares, a decrease of 17.8% from the October 15th total of 8,750,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is currently 6.4 days.

Autolus Therapeutics Stock Performance

Shares of AUTL traded up $0.07 during mid-day trading on Friday, reaching $3.08. 2,713,999 shares of the company’s stock traded hands, compared to its average volume of 1,442,195. Autolus Therapeutics has a 12 month low of $2.94 and a 12 month high of $7.45. The stock has a market capitalization of $819.56 million, a P/E ratio of -2.55 and a beta of 2.04. The business’s 50-day moving average price is $3.91 and its 200-day moving average price is $3.98.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the company posted ($0.26) EPS. Equities research analysts anticipate that Autolus Therapeutics will post -0.84 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on AUTL shares. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.45.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC grew its position in Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth $78,765,000. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after purchasing an additional 2,487,778 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.